Semaglutide Lowers Heart Filling Pressures in Patients With Obesity and HFpEF
A randomized trial found semaglutide reduced heart filling pressures, with normal readings at rest and exercise in over half of treated patients.
Riepilogo
Semaglutide may help explain more than symptom relief in patients with obesity and heart failure with preserved ejection fraction, a condition involving abnormally high heart filling pressures. In a randomized, placebo-controlled trial, 81 patients received weekly semaglutide or placebo for 52 weeks. During light exercise, filling pressure fell by 9.8 millimeters of mercury with semaglutide but rose by 0.9 with placebo. Resting pressure also improved. Normal pressures during both rest and exercise occurred in 53.7% of semaglutide recipients versus 7.4% receiving placebo. This represents normalization of measured pressures, not proof that heart failure was cured. The findings support discussing treatment with a clinician, but do not establish longer survival. This abstract-only summary cannot assess detailed safety results, and the small trial leaves uncertainty about lasting benefits.
Riepilogo Dettagliato
Heart failure with preserved ejection fraction means the heart can squeeze normally but still develops abnormally high filling pressures. These pressures can contribute to breathlessness and limited activity. For patients who also have obesity, understanding whether semaglutide reduces this congestion could help explain its previously reported symptom benefits and guide future treatment research.
In a double-blind randomized trial, researchers assigned 81 patients, including 47 women, to semaglutide or placebo for 52 weeks. The semaglutide dose was 2.4 milligrams weekly. The main outcome was the change in pressure measured invasively during low-intensity exercise. Researchers also assessed resting pressures and whether pressures returned to normal during both rest and exercise at the final assessment.
During exercise, pressure fell by 9.8 millimeters of mercury with semaglutide but rose by 0.9 with placebo. The estimated difference between groups was 10.6 millimeters of mercury in favor of semaglutide. Resting pressure was also lower by an estimated 7.1 millimeters of mercury. Both comparisons were statistically significant, supporting a treatment effect on these measurements.
Normal pressures at both rest and exercise occurred in 53.7% of semaglutide recipients versus 7.4% receiving placebo. Researchers called this hemodynamic remission, meaning normalization of measured filling pressures, not necessarily a cure. The findings support discussing semaglutide with a clinician when obesity accompanies this heart failure subtype, while continuing established heart failure care rather than replacing it.
Important uncertainties remain. This summary relies on the abstract only, and the trial included just 81 patients followed for one year. The abstract does not report adverse events, weight changes, hospitalizations, or survival outcomes, so it cannot establish longer life or identify the precise mechanism. The remission estimate also has substantial statistical uncertainty. Larger studies should clarify durability, safety, and which patients benefit most. The lead author disclosed financial relationships with several companies, including semaglutide's manufacturer.
Risultati Principali
- Weekly semaglutide reduced exercise filling pressure by an estimated 10.6 mmHg versus placebo at 52 weeks; 95% confidence interval, 8.0–13.3 mmHg.
- Resting filling pressure was an estimated 7.1 mmHg lower with semaglutide than placebo.
- Normal pressures at rest and exercise occurred in 53.7% versus 7.4%; this measured remission does not establish a cure.
- Results apply to patients with obesity and HFpEF; discuss treatment suitability with a clinician rather than changing medication independently.
Metodologia
This double-blind, placebo-controlled randomized trial enrolled 81 patients with HFpEF and obesity, including 47 women, for 52 weeks of semaglutide 2.4 mg weekly or placebo. The primary endpoint was change in invasively measured pulmonary artery wedge pressure during low-intensity exercise; additional outcomes included resting pressure and normalization of pressures at both rest and exercise. The trial registration was NCT05371496.
Limitazioni dello Studio
This summary is based on the abstract only; the small sample and 52-week follow-up limit conclusions about durability and broader applicability. The abstract does not report adverse events, weight changes, hospitalizations, or mortality, and the remission odds ratio has a wide confidence interval of 3.0–134.6. The lead author disclosed research funding and consulting relationships with multiple companies, including Novo Nordisk.
Ti è piaciuto questo riepilogo?
Ricevi ogni settimana le ultime ricerche sulla longevità direttamente nella tua casella email.
Inserisci la tua email per iscriverti: